Q-omics provides the consensus-scored MIR1288 profile across patient tissues and cancer cell-line models. MIR1288 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MIR1288 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR1288 RNA expression shows 7,938 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight OV, BRCA, and LAML as cancer lineages where MIR1288 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1288 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1288 survival associations across molecular data types. MIR1288 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1288 RNA expression–survival associations across cancer types. High MIR1288 expression shows unfavorable associations in OV, KIRC, LUAD, ESCA and UCEC, but favorable associations in SKCM. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for MIR1288 RNA expression.
This table summarizes MIR1288 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1288. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1288 shows higher tumor expression in BRCA. The BRCA box plot shows higher MIR1288 RNA expression in tumor versus normal tissue (log2 FC = +0.154, t-test p = .049).
This table shows molecular features associated with MIR1288 in patient tissues and cancer cell lines. In patient samples, MIR1288 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
